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Sofosbuvir, Velpatasvir, and Voxilaprevir 
for Treatment of Recurrent Hepatitis 
C Virus Infection After Liver 
Transplantation
Maria G. Cardona-Gonzalez,1 Jason D. Goldman,1,2 Lawrence Narayan,1 Diana M. Brainard3, and Kris V. Kowdley1
There are limited data on direct-acting antiviral (DAA) treatment options for previously treated patients with recur-
rent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/
VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs. We report the 
first published experience using SOF/VEL/VOX after liver transplantation for a DAA-experienced patient with se-
vere hepatitis due to early recurrent GT3 HCV. The patient was treated with SOF/VEL/VOX that was extended to 
a total duration of 16 weeks and was intensified with ribavirin (RBV) starting at week 8 due to persistent viremia 
during treatment. Sustained virologic response at 12 weeks (SVR12) after treatment completion was achieved. SOF/
VEL/VOX was well tolerated, and immediate drug–drug interaction (DDI) with tacrolimus (TAC) was not evident. 
Due to improvement in liver metabolic function with increasing TAC clearance, TAC dose adjustment was required 
throughout the treatment course. Conclusion: SOF/VEL/VOX can be considered for treatment of recurrent HCV 
after transplantation. Further study is needed to establish safety and efficacy and define treatment duration in dif-
ficult-to-treat populations. (Hepatology Communications 2018;2:1446-1450).
Direct-acting antivirals (DAAs) for the treat-ment of hepatitis C virus (HCV) infection have dramatically changed the landscape to 
treat recurrent HCV after orthotopic liver transplan-
tation (OLT). Drug–drug interactions (DDIs) may 
influence the use of DAAs for treatment of HCV post-
OLT and may pose challenges to successful dosing of 
DAAs or anti-rejection medications. SOF/VEL/VOX 
is currently approved for treatment of HCV in patients 
with prior treatment with DAAs.(1) However, to our 
knowledge, use of this regimen has not been described 
in the post-OLT setting. We report our experience in 
using sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/
VOX) to treat a DAA-experienced patient with severe 
hepatitis due to early recurrent genotype 3 (GT3) HCV.
Patient and Methods
Case RepoRt
A 61-year-old male with a past medical history 
of diabetes, hypertension, and chronic back pain was 
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diagnosed with GT3 HCV in 1995. By January 2014, 
he had developed biopsy-proven cirrhosis; he had 
interlukin (IL) 28B GT CT.
The patient was first treated for HCV in February 
2014 with SOF and ribavirin (RBV) for 16 weeks as 
part of the Boson Study.(2) He achieved undetectable 
HCV RNA by week 8 through the end of treatment 
(EOT). However, HCV viremia recurred at 4 weeks 
after EOT, and he was subsequently retreated with 
SOF, RBV, and pegylated interferon alfa-2a for 12 
weeks. The patient developed anemia, insomnia, and 
fatigue but completed the treatment regimen. HCV 
RNA was undetectable at week 8 and sustained though 
EOT, but again viremia recurred at 4 weeks after EOT. 
During both these treatments, study investigators and 
clinicians assessed that the patient adhered assiduously 
to the treatment regimen. No nonstructural protein 5B 
(NS5B) resistance-associated substitutions were identi-
fied using a 15% deep sequencing cutoff at the baseline 
and treatment failure time points for both treatment 
attempts. NS5A genotyping was not performed. In 
March 2016, the patient was found to have hepatocel-
lular carcinoma (HCC) and was treated with radio fre-
quency ablation and transarterial chemoembolization.
The patient underwent OLT with exception 
points for HCC in August 2017. The donor was a 
trauma victim who was not HCV infected. Baseline 
laboratory testing prior to OLT showed white blood 
cell count 12.7 × 103/µL, hemoglobin 14.2 g/dL, 
platelets 164 × 103/µL, normal kidney function with 
creatinine 1.18 mg/dL, and liver function showing 
total bilirubin 0.6 mg/dL, alanine aminotransferase 
(ALT) 200 U/L, aspartate aminotransferase 119 U/L, 
and alkaline phosphatase 161 U/L. Induction immu-
nosuppression was high-dose methylprednisolone 
with taper, and the maintenance immunosuppres-
sion regimen included tacrolimus (TAC), myco-
phenolate mofetil, and prednisone. The immediate 
postoperative course was uncomplicated, but the 
patient was readmitted to the hospital on postop-
erative day (POD)9 with elevated liver enzymes. 
After OLT, ALT spiked to 447 U/L on POD1 and 
decreased to nadir 147 U/L on POD6 but increased 
to 487 U/L on POD9 (Fig. 1). Total bilirubin was 
3.6 mg/dL after transplant, decreased to 0.8 mg/dL 
on POD6, and increased only slightly to 0.9 mg/dL 
on POD9. Similarly, alkaline phosphatase was also 
not elevated. Biopsy showed portal inflammation, 
lymphocytic cholangitis, mild steatosis, and no evi-
dence for fibrosis, findings not diagnostic for acute 
rejection. POD11 HCV RNA was >100,000,000 
IU/mL, verified as GT3, confirming the diagnosis 
of acute allograft hepatitis due to recurrent HCV. 
The patient started SOF/VEL/VOX for recurrent 
HCV on POD15 for a planned treatment course of 
12 weeks. Although data in the post-OLT setting 
for SOF/VEL/VOX were lacking, this regimen was 
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Fig. 1. Treatment response of patient on DAA therapy with 
SOF/VEL/VOX. # indicates an HCV RNA level that was 
detected (<15 IU/mL) but below the limit of linear quantitation 
for the assay.
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chosen over the SOF/VEL combination(3) due to the 
high efficacy of SOF/VEL/VOX (≥95% sustained 
virologic response at 12 weeks [SVR12]) in phase 
3 studies in DAA-experienced patients infected 
with GT3 HCV.(1) Alternatively, options included 
in the American Association for the Study of Liver 
Diseases–Infectious Disease Society of America 
(AASLD/IDSA) guidelines at the time of DAA 
regimen initiation (August 2017) included daclat-
asvir (DCV) and SOF (DCV + SOF), but guidelines 
recommended extension to 24 weeks and addition of 
RBV.(4) At the time of regimen selection, AASLD-
IDSA guidelines did not include a recommendation 
for glecaprevir/pibrentasvir (GLE/PIB). Preliminary 
results from the MAGELLAN-2 trial of GLE/PIB 
in patients after OLT were not yet published but had 
been presented at the European Association for the 
Study of the Liver (EASL) 2017 international meet-
ing. The MAGELLAN-2 trial did not enroll any 
participants experienced in GT3 treatment.(5) In the 
context of no clear guidance for the multiple hard-
to-treat characteristics of our GT3 patient with mul-
tiple treatment experiences, we selected SOF/VEL/
VOX as the most potent and likely to be successful.
Results
After starting SOF/VEL/VOX, HCV viremia 
decayed rapidly with a >4 log10 drop in HCV 
RNA by week 2 but with a slower decrease in HCV 
RNA through week 8 when HCV RNA was first 
undetectable (Fig. 1). Due to detectable viremia at 
treatment weeks 4 and 6, the decision was made to 
extend therapy to 16 weeks. At week 8 of SOF/VEL/
VOX therapy, RBV was added. At week 10, HCV 
RNA was detectable but below the range of linear 
quantification for the assay (<15 IU/mL). With the 
addition of RBV, the patient developed insomnia, 
fatigue, and anemia and required blood transfusion. 
Antiviral treatment for HCV was completed in 
December 2017, and SVR was demonstrated at 4 
and 12 weeks after completing treatment.
Other medications during SOF/VEL/VOX treat-
ment included valganciclovir, zolpidem, omeprazole, 
furosemide, insulin, nebivolol, irbesartan, bupropion, 
and oxycodone. Neutropenia requiring filgrastim res-
cue developed in January 2018 and was ascribed to 
the anti-cytomegalovirus prophylaxis valganciclovir.
The immunosuppression strategy was not adjusted 
a priori before DAA treatment with SOF/VEL/VOX. 
TAC trough levels were monitored weekly and adjusted 
to goal levels per post-OLT protocol. Initially, no 
adjustment of the TAC dose was necessary after start-
ing SOF/VEL/VOX; however, over the course of the 
DAA treatment, TAC dose was slowly and progressively 
increased in response to weekly trough levels and the 
immunosuppression protocol. At DAA initiation, the 
daily dose was 2 mg, and at EOT the daily dose was 
5 mg, a 150% increase over the course of SOF/VEL/
VOX treatment. A normalized metric of TAC dosing 
(TAC level-to-dose ratio) decreased over the course of 
treatment (Fig. 2), indicating increasing TAC clearance.
Discussion
To our knowledge, we describe the first use of the 
pan-genotypic DAA therapy SOF/VEL/VOX for 
treatment of recurrent HCV after OLT. For recur-
rence in persons with GT3 HCV infection, AASLD-
IDSA guidelines recommend GLE/PIB or DCV + 
SOF; however, data for treatment-experienced persons 
in this setting are lacking.(4) The MAGELLAN-2 
study of GLE/PIB in posttransplant patients did not 
enroll any GT3 treatment-experienced participants.(5) 
Fig. 2. Effect of SOF/VEL/VOX on TAC clearance and liver 
metabolic function. The TAC level was normalized to the daily 
dose given 1 day prior to TAC level measurement. The TAC level-
to-dose ratio is inversely correlated with TAC clearance and liver 
metabolic function (see text).(9) An exponential decay curve was 
fit to the TAC level-to-dose data, excluding the three normalized 
levels immediately after OLT, as these were non-steady-state 
measurements, and preceding initiation.
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Although both GLE/PIB and DCV have potential 
to interact with TAC through weak cytochrome P450 
3A4 (CYP3A4) inhibition and permeability glycopro-
tein (P-gp) inhibition, respectively, neither regimen 
has been studied in DAA-experienced patients with 
GT3 HCV in the posttransplant setting. Treatment 
with SOF/VEL/VOX was selected from the available 
choices at the time due to our perception that this 
regimen would be the most potent in the context of 
multiple prior treatment failures and given the relative 
paucity of real-world information with GLE/PIB or 
DCV + SOF + RBV in the posttransplant setting for 
GT3 HCV infection after prior DAA treatment fail-
ures. At the time of regimen selection (August 2017), 
there was no clear option, and published data on expe-
rience with DAAs remain scant in difficult-to-treat 
populations, such as posttransplant, GT3, and treat-
ment experienced. Guidelines from AASLD-IDSA(4) 
concur with guidelines from EASL(6) in listing SOF/
VEL with weight-based RBV as an alternative reg-
imen for post-OLT treatment in GT3 patients. 
Although recent data have suggested excellent out-
comes for SOF/VEL without RBV in patients with 
GT3 and post-OLT HCV recurrence, we selected 
SOF/VEL/VOX on empirical grounds as the most 
potent regimen most likely to achieve cure given the 
paucity of data on patients similar to ours with DAA 
treatment experience, a history of HCC, and concur-
rent immunosuppression.(7)
Although treatment with SOF/VEL/VOX was 
well tolerated and effective, treatment extension to 16 
weeks and intensification with the addition of RBV 
were undertaken empirically to increase the probabil-
ity of a successful outcome. Initial response to SOF/
VEL/VOX showed rapid first-order kinetics and 
slower second-order kinetics. Detectable HCV RNA 
at weeks 4 and 6 prompted therapy extension of SOF/
VEL/VOX and intensification with RBV. Recurrent, 
low-level viremia (below the linear detection limit of 
the assay) was observed during the treatment course. 
Although common during the interferon era, data 
have not supported using response-guided therapy 
(i.e., treatment decisions based on viral decay kinet-
ics) with DAAs.(8) Nevertheless, the patient’s initial 
viral load of >10,000,000 IU/mL and viremia to 6 
weeks was not typical of the patients studied in clini-
cal trials, and therefore direct application of these data 
to our patient’s unique circumstances did not seem 
appropriate.
A major challenge of HCV treatment after OLT is 
the possible DDIs with immunosuppressive therapy. 
This is particularly evident with calcineurin inhibitors, 
as coadministration with SOF/VEL/VOX and cyclo-
sporine has been shown to substantially increase the 
plasma concentration of VOX in healthy adults with 
no studies assessing its safety. As a result, the coad-
ministration of SOF/VEL/VOX with cyclosporine is 
not recommended. Our patient was given TAC, which 
is a substrate for both CYP3A4 and P-gp and also 
a weak inhibitor for P-gp. Potential DDIs of TAC 
with SOF/VEL/VOX have not been systematically 
studied, although significant interactions requiring 
empiric dose modification are not anticipated. VOX 
is a substrate and inhibitor of P-gp and solute car-
rier organic anion transporter family member 1B1 
(OATP1B1) and OATP1B3 and is slowly metabo-
lized by CYP3A4. Careful monitoring of the TAC 
dose after initiation of SOF/VEL/VOX showed no 
immediate change in either the TAC level or TAC 
level-to-dose ratio, suggesting an absence of clinically 
significant DDIs. However, the TAC level-to-dose 
ratio continuously decreased over the course of SOF/
VEL/VOX treatment (Fig. 2). This ratio is inversely 
related to liver metabolic function or clearance of TAC 
and therefore liver enzymatic function.(9) Clearance 
of TAC and liver metabolic function increased over 
the course of SOF/VEL/VOX treatment. Our expe-
rience confirms that a priori TAC dose adjustment 
is not necessary, but continued close monitoring of 
TAC concentration during DAA therapy with SOF/
VEL/VOX is necessary to avoid subtherapeutic TAC 
dosing and the potential for allograft rejection. These 
findings suggest that acute hepatitis from recurrent 
HCV after OLT affects hepatic metabolic function 
and can be reversed with treatment of recurrent HCV.
DAAs have great promise for alleviating the 
morbidity and mortality of recurrent HCV after 
OLT. Difficult-to-treat populations exist, such as 
GT3 and treatment-experienced persons. SOF/
VEL/VOX represents a potent pan-genotypic reg-
imen that proved effective in this situation of mul-
tiple treatment failures and did not show clinically 
significant DDIs with TAC and other coadminis-
tered medications. Response-guided treatment in 
the DAA era may still be an important tool in diffi-
cult-to-treat persons. Because this was a single case, 
it is important to state that we cannot infer safety 
and efficacy when applying to a wider population. 
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Specifically, we cannot conclude from our experi-
ence if SOF/VEL/VOX alone for 12 weeks would 
have proved effective without RBV intensification 
or duration extension to 16 weeks. Additional data 
are needed in the posttransplant setting to further 
characterize the safety and efficacy of this regi-
men in this vulnerable population with high unmet 
medical need.
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